ABBV to Boost Immunology Pipeline With Capstan Buyout for $2.1B

• click to rate

  Posted by Two Blokes Jul 1 - Filed in Stock - 4 views
  
  AbbVie's $2.1 billion Capstan deal brings a novel in-vivo CAR-T therapy and tLNP platform to boost its immunology pipeline.